Table 4.

Changes from baseline in the WHO ordinal scale for clinical improvement (OSCI).

	hzVSF-v13 Low Dose	hzVSF-v13 High Dose	Placebo
Baseline
n	22	21	19
Mean (SD)	4.1 (0.7)	4.0 (0.6)	4.1 (0.6)
Day 14
n	20	21	19
Mean (SD)	2.0 (1.9)	2.4 (2.4)	2.7 (2.7)
Change from Baseline at Day 14
n	20	21	19
Mean (SD)	−2.1 (1.7)	−1.6 (2.2)	−1.4 (2.3)
p-value (Placebo vs. each hzVSF-v13)	0.5361	0.9109
p-value (Low hzVSF-v13 vs. High hzVSF-v13)		0.5936
Improved, n (%)	18 (90.00)	15 (71.4)	10 (52.6)
Not Improved, n (%)	2 (10.00)	6 (28.6)	9 (47.4)
Logistic Regression with Covariate at Day 14
Adjusted ORs	11.53	2.48
85% CI	[2.86, 46.49]	[0.84, 7.32]
p-value	0.0116	0.2266
Day 28
n	20	21	19
Mean (SD)	1.4 (1.9)	1.8 (2.3)	2.3 (3.0)
Change from Baseline at Day 28
n	20	21	19
Mean (SD)	−2.6 (1.7)	−2.2 (2.1)	−1.8 (2.6)
p-value (placebo vs. each hzVSF-v13)	0.5751	0.8818
p-value (low-dose hzVSF-v13 vs. high-dose hzVSF-v13)		0.5036
Improved, n (%)	18 (90.0)	18 (85.7)	13 (68.4)
Not Improved, n (%)	2 (10.0)	3 (14.3)	6 (31.6)
Logistic Regression with Covariate at Day 28
Adjusted ORs	4.39	2.78
85% CI	[1.19, 16.21]	[0.86, 9.02]
p-value	0.1032	0.2108